false2022-06-302022Q20001722926--12-31 0001722926 2022-01-01 2022-06-30 0001722926 2021-01-01 2021-06-30 0001722926 2021-12-31 0001722926 2022-06-30 0001722926 2021-01-01 2021-12-31 0001722926 2020-01-01 2020-12-31 0001722926 2020-12-31 0001722926 2021-02-25 2021-02-25 0001722926 2021-03-04 2021-03-04 0001722926 2022-02-28 0001722926 2021-06-30 0001722926 asln:LoansFromGovernmentAndInterestPayablesMember 2021-12-31 0001722926 ifrs-full:OrdinarySharesMember 2021-12-31 0001722926 asln:AmericanDepositaryShareMember 2021-12-31 0001722926 asln:LoansFromGovernmentMember 2021-12-31 0001722926 asln:OtherLongtermBorrowingsMember 2021-12-31 0001722926 asln:InterestPayablesMember 2021-12-31 0001722926 ifrs-full:OrdinarySharesMember asln:AtmSalesAgreementMember 2021-12-31 0001722926 asln:AmericanDepositaryShareMember asln:AtmSalesAgreementMember 2021-12-31 0001722926 ifrs-full:RecurringFairValueMeasurementMember 2021-12-31 0001722926 ifrs-full:Level3OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2021-12-31 0001722926 asln:JaguahrTherapeuticsPteLtdMember 2021-12-31 0001722926 asln:LoansFromGovernmentAndInterestPayablesMember 2022-06-30 0001722926 asln:ShortTermInvestmentsMember 2022-06-30 0001722926 asln:ShortTermInvestmentsMember asln:CorporateFixedIncomeMember 2022-06-30 0001722926 asln:ShortTermInvestmentsMember asln:CommercialPapersMember 2022-06-30 0001722926 asln:ShortTermInvestmentsMember asln:USGovernmentTreasuriesMember 2022-06-30 0001722926 ifrs-full:OrdinarySharesMember 2022-06-30 0001722926 asln:AmericanDepositaryShareMember 2022-06-30 0001722926 ifrs-full:Level1OfFairValueHierarchyMember asln:ShortTermInvestmentsMember asln:USGovernmentTreasuriesMember 2022-06-30 0001722926 ifrs-full:Level2OfFairValueHierarchyMember asln:ShortTermInvestmentsMember asln:CommercialPaperMember 2022-06-30 0001722926 asln:ShortTermInvestmentsMember asln:CommercialPaperMember 2022-06-30 0001722926 ifrs-full:Level2OfFairValueHierarchyMember asln:ShortTermInvestmentsMember asln:CorporateBondsMember 2022-06-30 0001722926 asln:ShortTermInvestmentsMember asln:CorporateBondsMember 2022-06-30 0001722926 ifrs-full:Level1OfFairValueHierarchyMember asln:ShortTermInvestmentsMember 2022-06-30 0001722926 ifrs-full:Level2OfFairValueHierarchyMember asln:ShortTermInvestmentsMember 2022-06-30 0001722926 asln:LoansFromGovernmentMember 2022-06-30 0001722926 asln:OtherLongtermBorrowingsMember 2022-06-30 0001722926 asln:InterestPayablesMember 2022-06-30 0001722926 ifrs-full:BottomOfRangeMember asln:AslnJuly2013Member 2022-06-30 0001722926 ifrs-full:TopOfRangeMember asln:AslnJuly2013Member 2022-06-30 0001722926 asln:AslnJuly2014Member 2022-06-30 0001722926 asln:AslnJuly2015Member ifrs-full:BottomOfRangeMember 2022-06-30 0001722926 asln:AslnJuly2015Member ifrs-full:TopOfRangeMember 2022-06-30 0001722926 asln:AslnJuly2016Member 2022-06-30 0001722926 asln:AslnJuly2017Member 2022-06-30 0001722926 asln:AslnDecember2020Member 2022-06-30 0001722926 asln:AslnJanuaryToJuly2021Member ifrs-full:BottomOfRangeMember 2022-06-30 0001722926 asln:AslnJanuaryToJuly2021Member ifrs-full:TopOfRangeMember 2022-06-30 0001722926 asln:AslnJanuary2022Member 2022-06-30 0001722926 ifrs-full:InterestRateRiskMember 2022-06-30 0001722926 asln:TwoThousandAndFourteenPlanMember 2022-06-30 0001722926 asln:TwoThousandAndSeventeenPlanMember 2022-06-30 0001722926 asln:TwoThousandAndTwentyEquityIncentivePlanMember 2022-06-30 0001722926 asln:AslnAmericanDepositaryShareMember asln:TwoThousandAndFourteenPlanMember 2022-06-30 0001722926 asln:AslnAmericanDepositaryShareMember asln:TwoThousandAndSeventeenPlanMember 2022-06-30 0001722926 ifrs-full:RecurringFairValueMeasurementMember 2022-06-30 0001722926 ifrs-full:Level3OfFairValueHierarchyMember ifrs-full:RecurringFairValueMeasurementMember 2022-06-30 0001722926 asln:JaguahrTherapeuticsPteLtdMember 2022-06-30 0001722926 asln:LongTermIncentivePlanGrantedInTwoThousandSeventeenMember 2022-06-30 0001722926 asln:LongTermIncentivePlanGrantedInTwoThousandEighteenMember 2022-06-30 0001722926 asln:LongTermIncentivePlanGrantedInTwoThousandNineteenMember 2022-06-30 0001722926 ifrs-full:BottomOfRangeMember 2022-06-30 0001722926 ifrs-full:TopOfRangeMember 2022-06-30 0001722926 asln:TwoThousandAndFourteenPlanMember asln:AmericanDepositaryShareMember 2022-06-30 0001722926 asln:TwoThousandAndFourteenPlanMember ifrs-full:OrdinarySharesMember 2022-06-30 0001722926 asln:TwoThousandAndSeventeenPlanMember asln:AmericanDepositaryShareMember 2022-06-30 0001722926 asln:TwoThousandAndSeventeenPlanMember ifrs-full:OrdinarySharesMember 2022-06-30 0001722926 asln:AmendmentsToIas8Member 2022-01-01 2022-06-30 0001722926 asln:AmendmentsToIas12Member 2022-01-01 2022-06-30 0001722926 asln:AmendmentsToIas1AndIfrsPracticeStatement2Member 2022-01-01 2022-06-30 0001722926 asln:AmendementsToIfrs17Member 2022-01-01 2022-06-30 0001722926 asln:Ifrs17Member 2022-01-01 2022-06-30 0001722926 asln:AmendmentsToIas1Member 2022-01-01 2022-06-30 0001722926 asln:AmendmentsToIfrs3Member 2022-01-01 2022-06-30 0001722926 country:SG 2022-01-01 2022-06-30 0001722926 country:TW 2022-01-01 2022-06-30 0001722926 country:AU 2022-01-01 2022-06-30 0001722926 country:HK 2022-01-01 2022-06-30 0001722926 country:CN 2022-01-01 2022-06-30 0001722926 ifrs-full:RightofuseAssetsMember 2022-01-01 2022-06-30 0001722926 ifrs-full:OtherPropertyPlantAndEquipmentMember 2022-01-01 2022-06-30 0001722926 ifrs-full:ComputerEquipmentMember 2022-01-01 2022-06-30 0001722926 ifrs-full:CurrencyRiskMember 2022-01-01 2022-06-30 0001722926 ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember ifrs-full:Level3OfFairValueHierarchyMember 2022-01-01 2022-06-30 0001722926 ifrs-full:OrdinarySharesMember 2022-01-01 2022-06-30 0001722926 asln:AmericanDepositaryShareMember 2022-01-01 2022-06-30 0001722926 asln:AmendmentsToIfrs9Ias39Ifrs7Ifrs4AndIfrs1614Member 2022-01-01 2022-06-30 0001722926 asln:AslnJanuary2022Member 2022-01-01 2022-06-30 0001722926 asln:AslnJanuaryToJuly2021Member ifrs-full:TopOfRangeMember 2022-01-01 2022-06-30 0001722926 asln:AslnJanuaryToJuly2021Member ifrs-full:BottomOfRangeMember 2022-01-01 2022-06-30 0001722926 asln:AslnDecember2020Member 2022-01-01 2022-06-30 0001722926 asln:AslnJuly2017Member 2022-01-01 2022-06-30 0001722926 asln:AslnJuly2016Member 2022-01-01 2022-06-30 0001722926 asln:AslnJuly2015Member 2022-01-01 2022-06-30 0001722926 asln:AslnJuly2014Member 2022-01-01 2022-06-30 0001722926 ifrs-full:TopOfRangeMember asln:AslnJuly2013Member 2022-01-01 2022-06-30 0001722926 ifrs-full:BottomOfRangeMember asln:AslnJuly2013Member 2022-01-01 2022-06-30 0001722926 asln:TwoThousandAndTwentyEquityIncentivePlanMember 2022-01-01 2022-06-30 0001722926 asln:TwoThousandAndTwentyEquityIncentivePlanMember 2022-01-01 2022-06-30 0001722926 asln:TwoThousandAndTwentyEquityIncentivePlanMember asln:AmericanDepositaryShareMember 2022-01-01 2022-06-30 0001722926 asln:LicenseAgreementsMember asln:CSLLimitedMember 2022-01-01 2022-06-30 0001722926 country:SG asln:JaguahrTherapeuticsPteLtdMember 2022-01-01 2022-06-30 0001722926 country:SG asln:ASLANPharmaceuticalsPteLtdSingaporeMember 2022-01-01 2022-06-30 0001722926 asln:TwoThousandAndFourteenPlanMember 2022-01-01 2022-06-30 0001722926 country:US 2022-01-01 2022-06-30 0001722926 ifrs-full:InterestRateRiskMember 2022-01-01 2022-06-30 0001722926 asln:AlmirallMember asln:LicenseAgreementsMember 2022-01-01 2022-06-30 0001722926 ifrs-full:SharePremiumMember 2022-01-01 2022-06-30 0001722926 asln:ShareOptionsReserveMember ifrs-full:SharePremiumMember 2022-01-01 2022-06-30 0001722926 asln:LongTermIncentivePlanMember 2022-01-01 2022-06-30 0001722926 asln:LicenseAgreementsMember asln:CSLLimitedMember ifrs-full:TopOfRangeMember 2022-01-01 2022-06-30 0001722926 asln:OtherPayableMember 2022-01-01 2022-06-30 0001722926 ifrs-full:RetainedEarningsMember 2022-01-01 2022-06-30 0001722926 ifrs-full:OtherRelatedPartiesMember 2022-01-01 2022-06-30 0001722926 asln:JANKHowdenPtyLtdMember 2022-01-01 2022-06-30 0001722926 asln:AslnJanuaryToJuly2021Member 2022-01-01 2022-06-30 0001722926 asln:AslnJuly2013Member 2022-01-01 2022-06-30 0001722926 asln:InterestPayablesMember 2022-01-01 2022-06-30 0001722926 asln:LeaseLiabilitiesCurrentMember 2022-01-01 2022-06-30 0001722926 ifrs-full:LongtermBorrowingsMember 2022-01-01 2022-06-30 0001722926 asln:JaguahrTherapeuticsPteLtdMember 2022-01-01 2022-06-30 0001722926 asln:JaguahrTherapeuticsPteLtdMember 2022-01-01 2022-06-30 0001722926 asln:TwoThousandAndFourteenPlanMember 2022-01-01 2022-06-30 0001722926 asln:J.p.MorganChaseBankN.aMember 2022-01-01 2022-06-30 0001722926 asln:TwoThousandAndFourteenPlanMember ifrs-full:OrdinarySharesMember 2022-01-01 2022-06-30 0001722926 asln:TwoHVLoanAgreementMember 2022-01-01 2022-06-30 0001722926 asln:KTwoHVLoanAgreementMember 2022-01-01 2022-06-30 0001722926 asln:AslnJanuary2022Member ifrs-full:BottomOfRangeMember 2022-01-01 2022-06-30 0001722926 asln:AslnJanuary2022Member ifrs-full:TopOfRangeMember 2022-01-01 2022-06-30 0001722926 asln:JaguahrTherapeuticsPteLtdMember 2022-01-01 2022-06-30 0001722926 ifrs-full:RightofuseAssetsMember 2021-01-01 2021-06-30 0001722926 ifrs-full:OtherPropertyPlantAndEquipmentMember 2021-01-01 2021-06-30 0001722926 ifrs-full:ComputerEquipmentMember 2021-01-01 2021-06-30 0001722926 ifrs-full:CurrencyRiskMember 2021-01-01 2021-06-30 0001722926 ifrs-full:OrdinarySharesMember 2021-01-01 2021-06-30 0001722926 asln:AmericanDepositaryShareMember 2021-01-01 2021-06-30 0001722926 ifrs-full:IssuedCapitalMember 2021-01-01 2021-06-30 0001722926 ifrs-full:SharePremiumMember ifrs-full:OrdinarySharesMember 2021-01-01 2021-06-30 0001722926 ifrs-full:SharePremiumMember 2021-01-01 2021-06-30 0001722926 country:SG asln:JaguahrTherapeuticsPteLtdMember 2021-01-01 2021-06-30 0001722926 country:AU 2021-01-01 2021-06-30 0001722926 country:US 2021-01-01 2021-06-30 0001722926 country:HK 2021-01-01 2021-06-30 0001722926 country:CN 2021-01-01 2021-06-30 0001722926 asln:ASLANPharmaceuticalsPteLtdSingaporeMember country:SG 2021-01-01 2021-06-30 0001722926 asln:LongTermIncentivePlanGrantedInTwoThousandEighteenMember 2021-01-01 2021-06-30 0001722926 asln:LongTermIncentivePlanGrantedInTwoThousandSeventeenMember 2021-01-01 2021-06-30 0001722926 country:SG 2021-01-01 2021-06-30 0001722926 asln:TwoThousandAndFourteenPlanMember 2021-01-01 2021-06-30 0001722926 ifrs-full:InterestRateRiskMember 2021-01-01 2021-06-30 0001722926 asln:ShareOptionsReserveMember ifrs-full:SharePremiumMember 2021-01-01 2021-06-30 0001722926 asln:LongTermIncentivePlanMember 2021-01-01 2021-06-30 0001722926 ifrs-full:NoncontrollingInterestsMember 2021-01-01 2021-06-30 0001722926 ifrs-full:SharePremiumMember ifrs-full:OtherEquityInterestMember 2021-01-01 2021-06-30 0001722926 ifrs-full:RetainedEarningsMember 2021-01-01 2021-06-30 0001722926 ifrs-full:OtherRelatedPartiesMember 2021-01-01 2021-06-30 0001722926 asln:JANKHowdenPtyLtdMember 2021-01-01 2021-06-30 0001722926 ifrs-full:ShorttermBorrowingsMember 2021-01-01 2021-06-30 0001722926 asln:InterestPayablesMember 2021-01-01 2021-06-30 0001722926 asln:ShortTermBorrowingsFromRelatedPartiesMember 2021-01-01 2021-06-30 0001722926 asln:LeaseLiabilitiesCurrentMember 2021-01-01 2021-06-30 0001722926 asln:LeaseLiabilitiesNonCurrentMember 2021-01-01 2021-06-30 0001722926 ifrs-full:LongtermBorrowingsMember 2021-01-01 2021-06-30 0001722926 asln:JaguahrTherapeuticsPteLtdMember 2021-01-01 2021-06-30 0001722926 asln:J.p.MorganChaseBankN.aMember 2021-01-01 2021-06-30 0001722926 asln:JaguahrTherapeuticsPteLtdMember 2021-01-01 2021-06-30 0001722926 ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember ifrs-full:Level3OfFairValueHierarchyMember 2021-01-01 2021-12-31 0001722926 asln:AmericanDepositaryShareMember asln:AtmSalesAgreementMember 2021-01-01 2021-12-31 0001722926 asln:OtherPayableMember 2021-01-01 2021-12-31 0001722926 asln:JefferiesLlcMember 2021-01-01 2021-12-31 0001722926 asln:JaguahrTherapeuticsPteLtdMember 2021-01-01 2021-12-31 0001722926 asln:AtmSalesAgreementMember 2021-01-01 2021-12-31 0001722926 asln:TwoThousandAndTwentyEquityIncentivePlanMember 2021-01-01 2021-12-31 0001722926 asln:KTwoHVLoanAgreementMember 2021-01-01 2021-12-31 0001722926 asln:LoansFromGovernmentMember 2011-04-27 0001722926 asln:EmployeeShareOptionPlanMember 2020-12-10 2020-12-10 0001722926 asln:AmericanDepositaryShareMember asln:EmployeeShareOptionPlanMember 2020-12-10 2020-12-10 0001722926 asln:TwoThousandAndTwentyEmployeeShareOptionPlanMember 2020-12-15 2020-12-15 0001722926 ifrs-full:InterestRateRiskMember 2021-06-30 0001722926 asln:TwoThousandAndFourteenPlanMember 2021-06-30 0001722926 asln:TwoThousandAndSeventeenPlanMember 2021-06-30 0001722926 asln:AslnAmericanDepositaryShareMember asln:TwoThousandAndFourteenPlanMember 2021-06-30 0001722926 asln:AslnAmericanDepositaryShareMember asln:TwoThousandAndSeventeenPlanMember 2021-06-30 0001722926 asln:LongTermIncentivePlanGrantedInTwoThousandSeventeenMember 2021-06-30 0001722926 asln:LongTermIncentivePlanGrantedInTwoThousandEighteenMember 2021-06-30 0001722926 asln:LongTermIncentivePlanGrantedInTwoThousandNineteenMember 2021-06-30 0001722926 asln:TwoThousandAndSeventeenPlanMember 2017-09-01 2017-09-30 0001722926 asln:EventsAfterBalanceSheetDateMember asln:K2HealthVentureMember asln:SecuredLoanFacilityMember 2021-07-13 0001722926 asln:JaguahrTherapeuticsPteLtdMember 2019-10-15 2019-10-15 0001722926 asln:JaguahrTherapeuticsPteLtdMember ifrs-full:TopOfRangeMember 2021-04-28 2021-04-28 0001722926 asln:JaguahrTherapeuticsPteLtdMember ifrs-full:BottomOfRangeMember 2021-04-28 2021-04-28 0001722926 ifrs-full:OrdinarySharesMember asln:AtmSalesAgreementMember 2020-12-31 0001722926 asln:AmericanDepositaryShareMember asln:AtmSalesAgreementMember 2020-12-31 0001722926 asln:AmericanDepositaryShareMember asln:AtmSalesAgreementMember 2020-10-09 2020-12-31 0001722926 asln:LoansFromGovernmentMember 2011-04-27 2011-04-27 0001722926 asln:TwoThousandAndFourteenPlanMember 2010-07-01 2010-07-31 0001722926 asln:TwoThousandAndFourteenPlanMember ifrs-full:OrdinarySharesMember 2010-07-01 2010-07-31 0001722926 asln:TwoThousandAndTwentyEquityIncentivePlanMember 2022-01-01 2022-01-01 0001722926 asln:TwoThousandAndTwentyEquityIncentivePlanMember asln:AmericanDepositaryShareMember 2022-01-01 2022-01-01 0001722926 asln:TwoThousandAndTwentyEquityIncentivePlanMember asln:ModifiedShareOptionGrantedExercisePriceMember asln:AmericanDepositaryShareMember 2022-07-07 2022-07-07 0001722926 asln:TwoThousandAndTwentyEquityIncentivePlanMember 2022-07-07 2022-07-07 0001722926 asln:AtmSalesAgreementMember 2021-12-31 2021-12-31 0001722926 asln:SecondTrancheMember asln:TwoHVLoanAgreementMember ifrs-full:TopOfRangeMember 2022-01-05 2022-01-05 0001722926 asln:SecondTrancheMember asln:TwoHVLoanAgreementMember 2022-01-05 2022-01-05 0001722926 asln:TwoHVLoanAgreementMember 2022-01-05 0001722926 asln:SecondTrancheMember ifrs-full:OrdinarySharesMember asln:TwoHVLoanAgreementMember 2022-01-05 0001722926 asln:SecondTrancheMember asln:AmericanDepositaryShareMember asln:TwoHVLoanAgreementMember 2022-01-05 0001722926 asln:TwoHVLoanAgreementMember ifrs-full:OrdinarySharesMember 2022-01-05 0001722926 asln:TwoHVLoanAgreementMember asln:AmericanDepositaryShareMember 2022-01-05 0001722926 asln:KTwoHVLoanAgreementMember 2021-07-12 0001722926 asln:KTwoHVLoanAgreementMember ifrs-full:OrdinarySharesMember 2021-07-12 0001722926 asln:KTwoHVLoanAgreementMember asln:AmericanDepositaryShareMember 2021-07-12 0001722926 asln:KTwoHVLoanAgreementMember ifrs-full:TopOfRangeMember 2021-07-12 0001722926 asln:KTwoHVLoanAgreementMember asln:FirstTrancheMember 2021-07-12 0001722926 asln:KTwoHVLoanAgreementMember asln:SecondAndThirdTrancheMember 2021-07-12 0001722926 asln:KTwoHVLoanAgreementMember asln:FourthTrancheMember 2021-07-12 0001722926 asln:KTwoHVLoanAgreementMember 2021-07-12 2021-07-12 0001722926 ifrs-full:NoncontrollingInterestsMember 2021-12-31 0001722926 ifrs-full:ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember 2021-12-31 0001722926 ifrs-full:RetainedEarningsMember 2021-12-31 0001722926 ifrs-full:SharePremiumMember 2021-12-31 0001722926 ifrs-full:OtherEquityInterestMember ifrs-full:SharePremiumMember 2021-12-31 0001722926 asln:ShareOptionsReserveMember ifrs-full:SharePremiumMember 2021-12-31 0001722926 ifrs-full:OrdinarySharesMember ifrs-full:SharePremiumMember 2021-12-31 0001722926 ifrs-full:IssuedCapitalMember 2021-12-31 0001722926 asln:TwoThousandAndFourteenPlanMember 2021-12-31 0001722926 asln:TwoThousandAndSeventeenPlanMember 2021-12-31 0001722926 asln:TwoThousandAndTwentyEquityIncentivePlanMember 2021-12-31 0001722926 asln:LongTermIncentivePlanGrantedInTwoThousandSeventeenMember 2021-12-31 0001722926 asln:LongTermIncentivePlanGrantedInTwoThousandEighteenMember 2021-12-31 0001722926 asln:LongTermIncentivePlanGrantedInTwoThousandNineteenMember 2021-12-31 0001722926 asln:InterestPayablesMember 2021-12-31 0001722926 ifrs-full:LongtermBorrowingsMember 2021-12-31 0001722926 asln:LeaseLiabilitiesCurrentMember 2021-12-31 0001722926 ifrs-full:LongtermBorrowingsMember 2022-06-30 0001722926 asln:LeaseLiabilitiesCurrentMember 2022-06-30 0001722926 asln:InterestPayablesMember 2022-06-30 0001722926 ifrs-full:NoncontrollingInterestsMember 2022-06-30 0001722926 ifrs-full:ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember 2022-06-30 0001722926 ifrs-full:RetainedEarningsMember 2022-06-30 0001722926 ifrs-full:SharePremiumMember 2022-06-30 0001722926 ifrs-full:SharePremiumMember ifrs-full:OtherEquityInterestMember 2022-06-30 0001722926 ifrs-full:SharePremiumMember asln:ShareOptionsReserveMember 2022-06-30 0001722926 ifrs-full:SharePremiumMember ifrs-full:OrdinarySharesMember 2022-06-30 0001722926 ifrs-full:IssuedCapitalMember 2022-06-30 0001722926 ifrs-full:NoncontrollingInterestsMember 2020-12-31 0001722926 ifrs-full:ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember 2020-12-31 0001722926 ifrs-full:RetainedEarningsMember 2020-12-31 0001722926 ifrs-full:SharePremiumMember 2020-12-31 0001722926 ifrs-full:OtherEquityInterestMember ifrs-full:SharePremiumMember 2020-12-31 0001722926 asln:ShareOptionsReserveMember ifrs-full:SharePremiumMember 2020-12-31 0001722926 ifrs-full:OrdinarySharesMember ifrs-full:SharePremiumMember 2020-12-31 0001722926 ifrs-full:IssuedCapitalMember 2020-12-31 0001722926 asln:TwoThousandAndFourteenPlanMember 2020-12-31 0001722926 asln:TwoThousandAndSeventeenPlanMember 2020-12-31 0001722926 asln:LongTermIncentivePlanGrantedInTwoThousandSeventeenMember 2020-12-31 0001722926 asln:LongTermIncentivePlanGrantedInTwoThousandEighteenMember 2020-12-31 0001722926 asln:LongTermIncentivePlanGrantedInTwoThousandNineteenMember 2020-12-31 0001722926 asln:InterestPayablesMember 2020-12-31 0001722926 asln:ShortTermBorrowingsFromRelatedPartiesMember 2020-12-31 0001722926 ifrs-full:ShorttermBorrowingsMember 2020-12-31 0001722926 ifrs-full:LongtermBorrowingsMember 2020-12-31 0001722926 asln:LeaseLiabilitiesNonCurrentMember 2020-12-31 0001722926 asln:LeaseLiabilitiesCurrentMember 2020-12-31 0001722926 asln:InterestPayablesMember 2021-06-30 0001722926 ifrs-full:LongtermBorrowingsMember 2021-06-30 0001722926 asln:LeaseLiabilitiesNonCurrentMember 2021-06-30 0001722926 asln:LeaseLiabilitiesCurrentMember 2021-06-30 0001722926 ifrs-full:NoncontrollingInterestsMember 2021-06-30 0001722926 ifrs-full:ReserveOfGainsAndLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeMember 2021-06-30 0001722926 ifrs-full:RetainedEarningsMember 2021-06-30 0001722926 ifrs-full:SharePremiumMember 2021-06-30 0001722926 ifrs-full:SharePremiumMember ifrs-full:OtherEquityInterestMember 2021-06-30 0001722926 ifrs-full:SharePremiumMember asln:ShareOptionsReserveMember 2021-06-30 0001722926 ifrs-full:SharePremiumMember ifrs-full:OrdinarySharesMember 2021-06-30 0001722926 ifrs-full:IssuedCapitalMember 2021-06-30 iso4217:USD xbrli:pure iso4217:SGD xbrli:shares utr:Year asln:Segment iso4217:USD xbrli:shares utr:Day utr:D utr:Y
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM
6-K
 
 
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE
13a-16
OR
15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
August 12, 2022
(Commission File
No. 001-38475)
 
 
ASLAN PHARMACEUTICALS LIMITED
(REG. NO. 289175)
(Translation of registrant’s name into English)
 
 
CAYMAN ISLANDS
(Jurisdiction of incorporation or organization)
83 CLEMENCEAU AVENUE
#12-03
UE SQUARE
SINGAPORE 239920
(Address of registrant’s principal executive office)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover Form
20-F
or Form
40-F.
Form
20-F
☒        Form
40-F
☐
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101 (b) (1):
Yes ☐        No ☒
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101 (b) (7):
Yes ☐        No ☒
 
 
 
Announcement of Second Quarter 2022 Financial Results and Corporate Update
On August 12, 2022, ASLAN Pharmaceuticals Limited (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2022 and providing an update on recent corporate activities.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Financial Statements
On August 12, 2022, the Company issued its condensed consolidated financial statements for the six months ended June 30, 2022 (the “Financial Statements”).
A copy of the Financial Statements is attached hereto as Exhibit 99.2 and is incorporated by reference herein.
The information contained in this Form
6-K
is hereby incorporated by reference into the Company’s Registration Statement on
Form F-3
(File
No. 333-234405),
Registration Statement on
Form F-3
(File
No. 333-252575),
Registration Statement on
Form F-3
(File
No. 333-254768),
Registration Statement on Form
S-8
(File
No. 333-252118)
and Registration Statement on
Form S-8
(File
No. 333-263843).
Forward Looking Statements
This Form
6-K
contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of the Company. These forward-looking statements may include, but are not limited to, statements regarding the Company’s business strategy and clinical development plans; the Company’s plans to develop and commercialize
eblasakimab
and
farudodsta
; the safety and efficacy of
eblasakimab
and
farudodstat
; the potential of
eblasakimab
as a
first-in-class
treatment for atopic dermatitis and of
farudodstat
as a treatment for autoimmune disease; and the Company’s cash runway. The Company’s estimates, projections and other forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation the risk factors described in the Company’s U.S. Securities and Exchange Commission (the “SEC”) filings and reports (Commission File
No. 001-38475),
including the Company’s Annual Report on Form
20-F
filed with the SEC on March 25, 2022.
All statements other than statements of historical fact are forward-looking statements. The words “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement.
Exhibits
 
Exhibit
Number
  
Exhibit Description
99.1
  
99.2
  
101.INS
  
XBRL Instance Document
101.SCH
  
XBRL Taxonomy Extension Schema Document
101.CAL
  
XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
  
XBRL Taxonomy Extension Definition Linkbase Document
101.LAB
  
XBRL Taxonomy Extension Label Linkbase Document
101.PRE
  
XBRL Taxonomy Extension Presentation Linkbase Document
104
  
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
 
 
 
ASLAN PHARMACEUTICALS LIMITED
(Registrant)
 
 
By:
 
/s/ Kiran Kumar Asarpota
 
 
Name:
 
Kiran Kumar Asarpota
 
 
Title:
 
Chief Operating Officer
Date: August 12, 2022
ASLAN Pharmaceuticals (NASDAQ:ASLN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more ASLAN Pharmaceuticals Charts.
ASLAN Pharmaceuticals (NASDAQ:ASLN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more ASLAN Pharmaceuticals Charts.